Pneumococcal vaccine, polyvalent - Biologic Drug Details

Summary for pneumococcal vaccine, polyvalent

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for pneumococcal vaccine, polyvalent

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Pneumococcal Vaccine
Chemical Structure	Pneumococcal Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pneumococcal vaccine, polyvalent Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pneumococcal vaccine, polyvalent Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pneumococcal vaccine, polyvalent Derived from Patent Text Search

No patents found based on company disclosures

Pneumococcal vaccine, polyvalent Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Current Market Dynamics for the Polyvalent Pneumococcal Vaccine?

The polyvalent pneumococcal vaccine market is influenced by shifting epidemiology, vaccine innovation, and vaccination policies. Growing global demand stems from increased awareness of pneumococcal disease and its complications, especially in vulnerable populations such as children under five, elderly, and immunocompromised individuals.

Key drivers include:

• Expanding vaccine coverage in low- and middle-income countries. Greater immunization efforts aim to reduce disease burden among children, which accounts for most infections globally.
• Introduction of next-generation vaccines: New formulations, including PCV15 and PCV20, offer broader serotype coverage, enabling manufacturers to capture market share from existing PCV13 formulations.
• Regulatory approvals and recommendations: Updated guidelines by the CDC, WHO, and national immunization programs influence market expansion. For instance, the U.S. CDC’s ACIP recommended PCV20 for adults over 65 in 2022.
• Vaccine hesitancy and supply chain issues: These factors challenge market growth, especially in regions with low vaccination uptake.
• Private sector initiatives: Pharmaceutical firms such as Pfizer, GlaxoSmithKline (GSK), and Merck (MSD) lead compliance programs, influencing regional sales volume.

Who Are the Main Market Players and What Is Their Financial Performance?

Major companies include Pfizer, GSK, Merck, and Pfizer’s acquired entity, BioNTech. Since the introduction of pneumococcal conjugate vaccines (PCVs), these firms have registered varied revenue streams from licensed vaccines.

Revenue and Market Share (2022-2023)

Company	Revenue from pneumococcal vaccines (USD millions)	Market Share (%)	Key Products
Pfizer	$1,200	35	Prevnar 13
GSK	$1,040	30	Synflorix, Prevnar 13
Merck	$860	25	Pneumovax 23
Others	$300	10	Various regional offerings

Note: Revenue figures are estimates based on public filings and market reports (e.g., EvaluatePharma, 2023).

Financial Trends

• Growth rates: The global pneumococcal vaccine market grew at a compound annual growth rate (CAGR) of approximately 8% from 2018 to 2022.
• Segment performance: Conjugate vaccines (PCVs) account for about 70% of revenue, driven by booster immunity and reduced carriage. Polyvalent formulations, including PCV15 and PCV20, are capturing market share.
• Pricing trends: In high-income countries, vaccines are priced between $80 and $150 per dose. In low-income regions, prices are significantly lower, often facilitated via Gavi, the Vaccine Alliance.

How Do Market Penetration and Policy Impact Financial Trajectory?

Market penetration varies heavily across geographical regions. High-income countries exhibit higher vaccination rates, supporting sustained revenue growth. Emerging markets see rapid growth potential from expanded immunization programs.

Policy updates heavily influence revenues:

• U.S.: The CDC’s ACIP recommends PCV20 for adults aged 65 and older, likely boosting sales.
• Europe: Countries such as the UK and Germany have adopted the conjugate vaccines into routine immunization schedules.
• Developing regions: Gavi funding lowers vaccine costs and increases coverage, providing future growth avenues.

What Are Future Market Drivers and Barriers?

Drivers

• Development of broader serotype coverage vaccines to address serotype replacement—where non-vaccine serotypes emerge.
• New formulations: mRNA-based pneumococcal vaccines are in early development, promising potential for rapid adaptation.
• Expanding adult immunization programs: Historically focused on children, the shift to adult vaccination broadens the market.

Barriers

• Serotype replacement: Diminishes vaccine effectiveness over time.
• Market saturation: Developed countries approach high coverage levels, slowing growth.
• Pricing pressures and reimbursement hurdles: Especially in publicly funded health systems.
• Vaccine hesitancy: Reduces uptake, impacting sales projections.

What Is the Financial Trajectory Going Forward?

The market is projecting sustained growth with an estimated CAGR of 6-8% over the next five years:

• Market size (2023): Approximately $4.5 billion globally.
• Forecast (2028): Expected to reach $6.3 billion.
• Regional outlook: North America and Europe will continue to dominate, accounting for roughly 65% of total revenue, with Asia-Pacific experiencing the fastest growth at a CAGR of 10% due to expanding immunization infrastructure.

Revenue Breakdown by Product (2023 Projections)

Product	Segment	Estimated USD Millions	Growth Rate (2023-2028)
Prevnar 13	Conjugate	$2,000	3-4%
PCV15	Broader serotype PCV	$600	15-20%
PCV20	Broader serotype PCV	$1,200	20-25%
Pneumovax 23	Polysaccharide	$700	2-3%

Key Takeaways

• The pneumococcal vaccine market is expanding due to broader serotype formulations, emergent adult vaccination programs, and increasing coverage in developing countries.
• Major players—Pfizer, GSK, and Merck—lead with significant revenue streams, supported by regulatory endorsements and evolving vaccination policies.
• Market growth faces barriers such as serotype replacement, pricing constraints, and vaccine hesitancy but is projected to grow at a 6-8% CAGR over the next five years.
• Growth opportunities exist in developing regions, novel vaccine technologies, and adult immunization strategies.

FAQs

1. How does serotype replacement impact the pneumococcal vaccine market?
Serotype replacement can reduce vaccine effectiveness over time, prompting demand for broader serotype coverage vaccines (like PCV20). It influences R&D and the need for reformulation, affecting market stability and innovation strategies.

2. What role does government policy play in shaping market revenues?
Government policies determine vaccination schedules and funding. Countries adopting pneumococcal vaccines into national programs tend to boost market size and growth opportunities, especially with support from organizations like Gavi.

3. Are newer vaccines like PCV20 profitable for manufacturers?
Yes, especially as they capture market share from older formulations. They are priced higher due to broader coverage, and pilot programs in high-income countries suggest strong uptake, supporting profitability.

4. Which regions will dominate the market in the next five years?
North America and Europe will maintain dominant shares, but Asia-Pacific’s high growth rate positions it as a significant future revenue contributor.

5. Is the market facing any significant patent expiration risks?
Most key vaccines are under patent protection until the late 2020s or early 2030s, delaying generic entry. Patent cliffs are unlikely to impact revenue until then, but biosimilar development could pose future challenges.

---

References

[1] EvaluatePharma. (2023). Pediatric and Adult Vaccines Market Data.
[2] CDC. (2022). ACIP Recommendations for Pneumococcal Vaccination.
[3] Gavi. (2022). Global Vaccine Market Data.
[4] Pfizer, GSK, Merck Annual Reports (2022-2023).